STOCK TITAN

ATAI Life Sciences N.V. Common Shares - ATAI STOCK NEWS

Welcome to our dedicated news page for ATAI Life Sciences N.V. Common Shares (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on ATAI Life Sciences N.V. Common Shares.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ATAI Life Sciences N.V. Common Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ATAI Life Sciences N.V. Common Shares's position in the market.

Rhea-AI Summary
Cognito Therapeutics appoints Greg Weaver as CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
management
-
Rhea-AI Summary
atai Life Sciences to participate in Jefferies Inaugural Biotech CNS/Neuro Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
atai Life Sciences completes Phase 1 study of VLS-01, a DMT formulation, with favorable safety profile and comparable systemic delivery to IV administration. Plans to optimize formulation for Phase 2 study in treatment-resistant depression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.1%
Tags
Rhea-AI Summary
atai Life Sciences to participate in the 2023 Cantor Fitzgerald Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
conferences
-
Rhea-AI Summary
atai Life Sciences to participate in upcoming September Investor Conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
conferences
-
Rhea-AI Summary
atai Life Sciences (NASDAQ: ATAI) reported Q2 2023 financial results and clinical program updates, highlighted by Phase 1 results of DMX-1002 for Opioid Use Disorder and a $227M cash position expected to fund operations into 1H 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
Rhea-AI Summary
atai Life Sciences announces results from Perception Neuroscience's Phase 1 study of PCN-101, a potential rapid-acting anti-depressant for at-home use
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
conferences
-
Rhea-AI Summary
atai Life Sciences reports Q1 2023 financial results and provides updates on clinical pipeline. RL-007 Phase 2b study initiated, GRX-917 shows potential anxiolytic effects, VLS-01 Phase 1 study expanded, COMP360 Phase 3 trial accelerated. $250M cash position expected to fund operations into 1H 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
none
ATAI Life Sciences N.V. Common Shares

Nasdaq:ATAI

ATAI Rankings

ATAI Stock Data

343.20M
126.68M
9.99%
28%
3.34%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BERLIN

About ATAI

who we are: atai is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. our mission: we are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. our approach: by pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.